ProductsPricingFree Market DashboardMarket News FeedScannerChartsHeatmapMarket SectorsTrack RecordMAD AcademyMCP Connector

KALA BIO, Inc. (KALA)

Nasdaq · Common stock · Pharmaceutical Preparations

$0.1908+0.00 (+0.58%)

As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.

KALA trades thinly or has a short history, so some panels below have little to show.

Follow KALA in real time

Real-time quotes, Pro Charting, the scanner and the alert feed on KALA and every other US listing.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Or open the free KALA chart →

KALA at a glance

Key statistics

$3.67M

Market capitalization

Previous close
$0.1897
Open
$0.2010
Day range
$0.1821 – $0.2051
Volume
234.0K
Average volume (30 sessions)
2.69M
Shares outstanding
19.34M
Earnings per share
$(0.52)
Price / book
0.4
Beta (1 year, vs SPY)
2.46

Where the price sits in its year

52-week range

0% of the range

Below the 52-week high
-99.8%
Above the 52-week low
+66.5%

Completed sessions through Oct 21, 2026

Technical snapshot

Below its 50-day and 200-day averages

20-day average
$0.3292-42.0%
50-day average
$0.5412-64.7%
200-day average
$7.92-97.6%
RSI (14)21.0

In the band below 30 that convention calls oversold. Weak trends can stay there for weeks.

+1.5%

1 week

-68.1%

1 month

-68.7%

3 months

-99.3%

Year to date

-99.6%

1 year

Price change over each window, from completed sessions. Past performance does not indicate future results.

Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.

The member platform, in real time

What members do with KALA

Every plan

KALA on Pro Charting

Every intraday interval in real time, the drawing kit and the full set of technical studies on KALA.

See the plans →

Every plan

Screen names like KALA

The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.

See the plans →

Analysis Tools Only

Set a price line on KALA

Put KALA on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.

See the plans →

Stock Alerts + Tools

Open alerts on KALA

See whether there is an open premium alert on KALA, with its entry, stop and exit, each one reviewed by an analyst before it is sent.

See the plans →

From the public news wire

KALA headlines

Market news →

SEC Form 4, most recent first

Insider filings

How to read these →

  • Lazar David E.

    −368.6K

    Chief Executive Officer, Director · Other acquisition or disposition

    · Dec 18, 2025

  • Lazar David E.

    +900.0K

    Chief Executive Officer, Director · Grant or award

    · Nov 24, 2025

  • Bazemore Todd

    −47.8K

    Director · Open-market sale

    $39.65K · Oct 22, 2025

  • Reumuth Mary

    −32.2K

    CHIEF FINANCIAL OFFICER · Open-market sale

    $26.75K · Oct 22, 2025

  • Kharabi Darius

    −20.8K

    CHIEF BUSINESS OFFICER · Open-market sale

    $17.27K · Oct 22, 2025

  • Reumuth Mary

    −967

    CHIEF FINANCIAL OFFICER · Open-market sale

    $792.94 · Oct 23, 2025

  • Iwicki Mark T

    −154.9K

    Director · Open-market sale

    $125.46K · Oct 23, 2025

  • Brazzell Romulus K

    −46.7K

    SEE REMARKS · Open-market sale

    $38.80K · Oct 22, 2025

About KALA BIO, Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Exchange
Nasdaq
Security
Common stock
Industry
Pharmaceutical Preparations
Headquarters
Arlington, MA
Employees
6
Listed since
Jul 20, 2017
Website
kalarx.com
Educational content only. MadStockAlerts provides market commentary, research, and educational content. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security. Trading and investing involve substantial risk, including loss of capital. See the Risk Disclosure and Customer Agreement.

Pick the desk that fits how you trade

Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.